Navigation Links
Dr. Rongxiang Xu, Patent Owner of Damaged Organ Regeneration, a Top Priority Addressed in the 2013 Presidential State of The Union, Files Lawsuit Against 2012 Nobel Laureate Dr. Yamanaka for Deception
Date:5/15/2013

LOS ANGELES, May 15, 2013 /PRNewswire/ -- On May 8, 2013, Dr. Rongxiang Xu , the founder of "human body regenerative restoration science" and a renowned life and medical scientist who is believed to be the only person who has patented the technology for direct regeneration of damaged organs has filed a lawsuit against Dr. Shinya Yamanaka , one of the winners of the 2012 Nobel Prize in Physiology or Medicine in the Superior Court of California, County of San Francisco. The lawsuit filed alleges, among other things, deception by Dr. Shinya Yamanaka .

(Photo: http://photos.prnewswire.com/prnh/20130515/LA14340)

According to Dr. Xu's attorney, a previous lawsuit was filed by Dr. Xu against the Nobel Assembly on December 3, 2012, urging the Assembly to clarify certain statements made in conjunction with awarding the 2012 Nobel Prize in Physiology or Medicine. Unfortunately, no response clarifying the truth about the science has been received as the case is still pending. Therefore, Dr. Xu has filed another lawsuit directly against Dr. Yamanaka, for alleged deceptive practices employed by Dr. Yamanaka.

Dr. Xu's attorney stated that Dr. Yamanaka's published statements labeling his artificially transgenic cell study as "induction of somatic cells into stem cells", which was the patented technology of Dr. Xu, has caused substantial damages to his reputation and company. Dr. Xu claims that Dr. Yamanaka has deceived a number of well-intentioned professionals into exploration and re
'/>"/>

SOURCE Mebo International; Ardent Law Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dr. Rongxiang Xu, Owner of Patented Technology to Regenerate Damaged Organs, Announces Lawsuit Against 2012 Nobel Laureate Dr. Shinya Yamanaka
2. PharmaDirections is Co-inventor on Second Issued Formulation Patent Entitled “Layered Pharmaceutical Formulations”
3. First patent issues on TAL effector technology
4. Wysebridge Patent Bar Review Supports the National Foundation for Celiac Awareness (NFCA) During Celiac Awareness Month
5. Provitro Biosciences Awarded First-Ever U.S. Patent For Large-Scale Production Of Bamboo Plants
6. mPhase Technologies Receives Issue Notification Of Key Patent
7. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
8. Stemedica Issued U.S. Patent For Ectodermal Stem Cells
9. Wysebridge Patent Bar Review Launches America Invents Act (AIA) Study Suite
10. Cancer Advances Announces Issuance of Three New Patents to Its Suite of Gastrin Inhibitor Products
11. DuPont Receives ‘Patents for Humanity’ Award for Groundbreaking Research to Improve Nutritional Profile of Staple Crop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 DTS ... to its Online Web Portal for Life Science organizations who ... to specify the subject matter of their documents in advance ... will help reduce time-to-delivery of translations, often a critical factor ...
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today ... R-Pharm, a leading Russian pharmaceutical company, to develop and ... Russian Federation , Turkey ... is a novel antibiotic for the treatment of bacterial ...
(Date:1/14/2014)... Communications, a leading provider of strategic communications services to corporations and ... the United States and Europe ... JD, is returning to the firm,s Washington, D.C. ... more than two years of service as Associate Commissioner for the ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. ... together with two institutes from the National Institutes of ... for bringing safer, more effective treatments to patients on ... Center for Advancing Translational Sciences (NCATS) and the National ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... United States in ... More Than a Decade, ... in diagnostic imaging, announced today that the U.S. Food,and Drug Administration ... intravenous use in,T1-weighted magnetic resonance imaging (MRI) of the liver to ...
... Board and Management Focused on Near-Term Milestones and Maintain ... ... DIEGO, July 8 /PRNewswire-FirstCall/ - MIGENIX Inc.,(TSX: MGI, OTC: MGIFF), ... requisition for a special meeting of shareholders,for the purpose of ...
... CFO-level financial and management services for technology and biotechnology companies, today ... office. Strickland is the latest partner to join the company's Boston ... ... Cambridge, MA (PRWEB) July 8, 2008 -- TechCFO, a leading ...
Cached Biology Technology:FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 2FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 3FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 4FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 5FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 6FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 7MIGENIX Corporate Update and Requisition of Special Meeting 2MIGENIX Corporate Update and Requisition of Special Meeting 3MIGENIX Corporate Update and Requisition of Special Meeting 4MIGENIX Corporate Update and Requisition of Special Meeting 5MIGENIX Corporate Update and Requisition of Special Meeting 6MIGENIX Corporate Update and Requisition of Special Meeting 7MIGENIX Corporate Update and Requisition of Special Meeting 8TechCFO Adds Gary Strickland as Partner in Boston Office 2
(Date:4/16/2014)... the world? Surprisingly, bacteria also face this problem. Theoretical ... how these organisms should decide how best to preserve ... is quite adaptable. It moves about in liquids and ... can stick to an underlying substrate. Actually, the bacteria ...
(Date:4/15/2014)... April 15, 2014, Irvine, Calif. UC Irvine neurobiologists have ... when transplanted into the brains of mice with the symptoms ... in the journal Stem Cells Research and Therapy , ... different mouse models. , Alzheimer,s disease, one of the ...
(Date:4/15/2014)... study of nearly 1,000 mother-child pairs, researchers from the ... to selective serotonin reuptake inhibitors (SSRIs), a frequently prescribed ... with autism spectrum disorder (ASD) and developmental delays (DD) ... of Pediatrics , analyzed data from large samples ...
Breaking Biology News(10 mins):Theoretical biophysics: Adventurous bacteria 2UCI study finds modified stem cells offer potential pathway to treat Alzheimer's disease 2Study: SSRI use during pregnancy associated with autism and developmental delays in boys 2
... be best known for their supersized canines, but they also ... fatal bite, says a new study in the journal ... extinct cat Smilodon fatalis roamed North and South ... as bison, camels, mastodons and mammoths. Telltale clues from bones ...
... While pregnant women may worry about the effects of air ... exposure to carbon monoxide and fine particles in the air ... preterm delivery or preeclampsia -- a serious condition that arises ... headed by a University at Buffalo epidemiologist. , The ...
... cell decide its particular identity? According to biologists at ... of T cellsimmune system cells that help destroy invading ... particular gene called Bcl11b. The activation of Bcl11b ... have decided to go on the T-cell pathway," says ...
Cached Biology News:Why you should never arm wrestle a saber-toothed tiger 2Air pollution doesn't increase risk of preeclampsia, early delivery, study finds 2Caltech biologists discover how T cells make a commitment 2Caltech biologists discover how T cells make a commitment 3
BAFF-R (CT) BR3 Affinity Purified Polyclonal Antibody...
HOXC11 Antibody...
HOXC11 Antibody...
PMM2 Immunogen: PMM2 (NP_000294, 47 a.a. ~ 112 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: